Mathematical modelling approaches to virtual clinical trials

About SMB Forums Conferences Mathematical modelling approaches to virtual clinical trials

Viewing 1 post (of 1 total)
  • Author
  • #7579
    BIRS Facilitator

    The Banff International Research Station (BIRS) is pleased to announce our next Career & Innovation Hub workshop “Mathematical modelling approaches to virtual clinical trials”. This event will take place virtually on May 1-2, 2022 (11:30AM – 2PM daily MST). The event is completely free for participants but registration is mandatory.

    This workshop will equip participants from mathematics and related disciplines with the tools necessary to solve common drug development questions in the pharmaceutical industry. The focus will be on development of pharmacometrics skills to approach questions centred on drug discovery and in silico (virtual) clinical trials using a variety of state-of-the-art model-informed drug development (MIDD), including quantitative systems pharmacology (QSP) methodologies. The workshop’s sessions will highlight modern modeling and simulation approaches applied to diverse pre- and post-clinical drug development questions, including methodological aspects of virtual clinical trial implementation, and the use of in silico clinical trials in immuno-oncology and other key drug development spaces.

    Please visit the following URL to register:

    The workshop includes seminars with mathematicians from leaders in the pharmaceutical industry including Pfizer, Takeda and Notch Therapeutics. Opportunities for participant/speaker interactions will be emphasized during the program – including allowed time for breakout rooms with event speakers and audience Q&A.

    This event will take place virtually via Zoom. Visit the workshop webpage to see the speaker list and schedule.

    Workshop webpage:

    If you have any questions about the program please reach out via e-mail to


    You must be logged in to view attached files.
Viewing 1 post (of 1 total)
  • You must be logged in to reply to this topic.

Comments are closed.